The GFR-Vivo™ 680 imaging agent is the first fluorescent agent that allows researchers to measure glomerular filtration rate (GFR) non-invasively, in vivo in animals. GFR-Vivo 680, in combination with Fluorescence Molecular Tomography (FMT) imaging, provides a non-invasive approach to generate consistent GFR measurements in animal models of kidney disease, dysfunction, and drug toxicity.
GFR is the leading standard for measuring kidney function and is used to determine progression of kidney disease as well as drug-induced kidney toxicity. This agent allows researchers to get an accurate read out of GFR in vivo without the need for blood or urine sampling or labor intensive microplate assays. This fluorescent imaging agent is well-suited for researchers studying in vivo toxicology or drug safety assessment.
The GFR-Vivo™ 680 was launched at this year’s Society of Toxicology’s 52nd Annual Meeting and ToxExpo in a presentation entitled, “Novel Near Infrared Agent for Non-Invasive Imaging and Quantification of Glomerular Filtration Rate in Mice.” PerkinElmer also plans to feature the new imaging agent at booth #1424 at the American Association for Cancer Research (AACR) Annual Meeting from April 6 – 10.
Learn more about GFR-Vivo 680 fluorescent imaging agent by reviewing the application note “An in vivo non-invasive method to determine glomerular filtration rate (GFR)” or join an informational webinar on April 24 at 1:00 PM (EST)
If interested in scheduling a one-on-one conversation with a PerkinElmer expert, please contact:
Edelman (on behalf of PerkinElmer)
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.